Teduglutide
Also known as: Gattex, Revestive, ALX-0600
A GLP-2 analog that boosts intestinal absorption in short bowel syndrome. FDA-approved as Gattex since 2012. Prescription medication.
Last updated
Mechanism of Action
Teduglutide is a 33-amino-acid analog of glucagon-like peptide-2 (GLP-2) with a single glycine-for-alanine substitution at position 2 that slows breakdown by dipeptidyl peptidase-4. It activates GLP-2 receptors on enteroendocrine cells and subepithelial myofibroblasts, which release mediators such as IGF-1 and keratinocyte growth factor. The result is increased villus height and crypt depth, greater intestinal blood flow and slower gastric emptying, improving fluid and nutrient absorption in the remaining bowel.
- Half-life
- ~2 hours (subcutaneous, healthy adults); ~1.3 hours in short bowel syndrome
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Reduces parenteral support volume in adults with short bowel syndrome
- Allows some patients to reduce days on parenteral support
- Approved for children 1 year and older with short bowel syndrome dependent on parenteral support
Potential Side Effects
- Abdominal pain and distension
- Injection-site reactions
- Nausea
- Warnings for accelerated growth of intestinal polyps or neoplasms
- Intestinal obstruction, gallbladder, bile duct and pancreatic disease, and fluid overload
Common Dosing
Labeled dosing is 0.05 mg/kg by subcutaneous injection once daily, with colonoscopy and polyp surveillance before and during treatment and ongoing adjustment of parenteral support. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active gastrointestinal malignancy (label warning: discontinue)
- Intestinal obstruction
- Known hypersensitivity to teduglutide
No documented stacking partners for Teduglutide yet.
- View
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
2011
- View
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure
2012
- View
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study
2020